There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Haemonetics (HAE – Research Report), Daré Bioscience (DARE – Research Report) and Kala Pharmaceuticals (KALA – Research Report) with bullish sentiments.
Haemonetics (HAE)
In a report issued on August 8, Anthony Petrone from Mizuho Securities assigned a Buy rating to Haemonetics, with a price target of $115.00. The company’s shares closed last Friday at $91.15.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of
Currently, the analyst consensus on Haemonetics is a Strong Buy with an average price target of $110.00, representing a 21.0% upside. In a report issued on August 9, Barrington also maintained a Buy rating on the stock with a $114.00 price target.
See today’s best-performing stocks on TipRanks >>
Daré Bioscience (DARE)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Daré Bioscience yesterday and set a price target of $4.00. The company’s shares closed last Friday at $0.75, close to its 52-week low of $0.66.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Daré Bioscience with a $5.50 average price target, implying a 648.3% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.
Kala Pharmaceuticals (KALA)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Kala Pharmaceuticals today and set a price target of $24.00. The company’s shares closed last Friday at $13.72.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kala Pharmaceuticals with a $31.50 average price target, which is a 126.5% upside from current levels. In a report issued on August 4, Wedbush also reiterated a Buy rating on the stock with a $39.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HAE:
- Haemonetics price target raised to $114 from $111 at Barrington
- Haemonetics raises FY24 adjusted EPS view to $3.60-$3.90 from $3.45-$3.75
- Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- Haemonetics reports Q1 adjusted EPS $1.05, consensus 73c
- HAE Earnings this Week: How Will it Perform?
